½ÃÀ庸°í¼­
»óǰÄÚµå
1663515

¼¼°èÀÇ CRISPR/Cas À¯ÀüÀÚ ½ÃÀå : Á¦Ç°º°, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº°, ±¹°¡º°, Áö¿ªº° - »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, Á¡À¯À², ¿¹Ãø(2025-2032³â)

CRISPR and Cas Gene Market, By Product, By Application, By End-User, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: AnalystView Market Insights | ÆäÀÌÁö Á¤º¸: ¿µ¹® 303 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

º¸°í¼­ ÇÏÀ̶óÀÌÆ®

CRISPR/Cas À¯ÀüÀÚ ½ÃÀå ±Ô¸ð´Â 2024³â 48¾ï 9,943¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2025-2032³â°£16.90%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î È®´ëµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

CRISPR/Cas À¯ÀüÀÚ ½ÃÀå ¿ªÇÐ

ÀÇ·á ¹× ³ó¾÷ ºÐ¾ß¿¡¼­ Á¤¹ÐÇÑ À¯ÀüÀÚ ÆíÁý µµ±¸¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡

CRISPR/Cas ½Ã½ºÅÛ°ú °°Àº Á¤¹Ð À¯ÀüÀÚ ÆíÁý µµ±¸¿¡ ´ëÇÑ ¼ö¿ä´Â ÀÇ·á ¹× ³ó¾÷ ºÐ¾ß¿¡¼­ Çõ½Å °¡´É¼º°ú ºñ¿ë È¿À²¼ºÀ¸·Î ÀÎÇØ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù. ÀÇ·á ºÐ¾ß¿¡¼­ CRISPRÀº Áúº´À» À¯¹ßÇÏ´Â µ¹¿¬º¯À̸¦ Á÷Á¢ ±³Á¤ÇÔÀ¸·Î½á À¯ÀüÀÚ Áúȯ¿¡ ´ëÇÑ È¹±âÀûÀÎ Ä¡·á¸¦ °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ¿¹¸¦ µé¾î, °â»ó ÀûÇ÷±¸ ºóÇ÷°ú º£Å¸ ÁöÁßÇØ ºóÇ÷ Ä¡·á¿¡¼­ À¯¸ÁÇÑ °á°ú¸¦ º¸¿©ÁÖ¾ú½À´Ï´Ù. ¶ÇÇÑ, ÀÌ ±â¼úÀº À¯ÀüÀÚ Á¶ÀÛ T¼¼Æ÷°¡ ƯÁ¤ Á¾¾ç ¼¼Æ÷¸¦ Ç¥ÀûÀ¸·Î »ï´Â ¾Ï ¸é¿ª Ä¡·á¿¡µµ ¸Å¿ì Áß¿äÇϸç, °³ÀÎ ¸ÂÃãÇü ÀǷḦ ¹ßÀü½Ãų ¼ö ÀÖ½À´Ï´Ù. Àü ¼¼°èÀûÀ¸·Î ¼ö¹é¸¸ ¸í¿¡°Ô ¿µÇâÀ» ¹ÌÄ¡´Â À¯Àü¼º Áúȯ Áõ°¡´Â Ä¡·á ¿¬±¸¿¡ CRISPR ±â¼úÀ» äÅÃÇÏ´Â Áß¿äÇÑ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¼¼°èº¸°Ç±â±¸(WHO)¿¡ µû¸£¸é, ¾à 1¸¸¿© Á¾ÀÇ ´Ü¹ß¼º ÁúȯÀÌ À¯ÀüÀÚ ÆíÁýÀÇ ¹ßÀüÀ¸·Î Ä¡·áµÉ °¡´É¼ºÀÌ ÀÖ´Ù°í ÇÕ´Ï´Ù. ³ó¾÷ ºÐ¾ß¿¡¼­ CRISPRÀº ÀÛ¹° °øÇÐÀ» ÀçÁ¤ÀÇÇÏ°í °úÇÐÀÚµéÀÌ ÇØÃæ ÀúÇ×¼º, °¡¹³ ÀúÇ×¼º, ¿µ¾ç °­È­ ÀÛ¹°À» °³¹ßÇÏ¿© ½Ä·® ºÒ¾È¿¡ ´ëóÇÒ ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù. ¶ÇÇÑ, È­ÇÐ ³ó¾à°ú È­ÇÐ ºñ·á¿¡ ´ëÇÑ ÀÇÁ¸µµ¸¦ ÁÙÀÓÀ¸·Î½á Áö¼Ó °¡´ÉÇÑ ³ó¾÷À» Áö¿øÇϰí ÀÖ½À´Ï´Ù. ¹Ì±¹ ³ó¹«ºÎ(USDA)´Â 2023³â À¯ÀüÀÚ ÆíÁý ÀÛ¹°ÀÌ ÇâÈÄ 10³â°£ ½Ä·® »ý»êÀ» ÃÖ´ë 30%±îÁö ²ø¾î¿Ã¸± ¼ö ÀÖ´Ù°í º¸°íÇϸç, ÀÌ ±â¼úÀÌ ¼¼°è ³ó¾÷ ¹®Á¦¸¦ ÇØ°áÇÒ ¼ö ÀÖ´Â °¡´É¼ºÀ» °­Á¶Çß½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¾ß¿¡¼­ CRISPRÀÇ Ã¤ÅÃÀÌ Áõ°¡Çϰí ÀÖ´Â °ÍÀº ZFNÀ̳ª TALEN°ú °°Àº ±âÁ¸ ±â¼ú¿¡ ºñÇØ Á¤¹Ð¼º, È¿À²¼º, °æÁ¦¼ºÀÌ ¶Ù¾î³ª±â ¶§¹®À̸ç, ÀÇ·á¿Í ½Ä·® »ý»ê ¸ðµÎ¿¡¼­ °ÔÀÓ Ã¼ÀÎÀú°¡ µÇ°í ÀÖ½À´Ï´Ù.

CRISPR/Cas À¯ÀüÀÚ ½ÃÀå : ÁÖ¿ä °íÂû

  • ´ç»çÀÇ ¸®¼­Ä¡ ¾Ö³Î¸®½ºÆ®µéÀÌ °øÀ¯ÇÑ ºÐ¼®¿¡ µû¸£¸é, ¼¼°è ½ÃÀåÀº ¿¹Ãø ±â°£(2025-2032³â) µ¿¾È ¾à 16.90%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¸Å³â ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • Á¦Ç°º°·Î´Â CRISPR Á¦Ç°ÀÌ 2024³â °¡Àå Å« ½ÃÀå Á¡À¯À²À» º¸¿´½À´Ï´Ù.
  • ÃÖÁ¾ »ç¿ëÀÚº°·Î´Â Á¦¾à ¹× »ý¸í°øÇÐ ±â¾÷ÀÌ 2024³â ÁÖ¿ä ±â¾÷ÀÔ´Ï´Ù.
  • Áö¿ªº°·Î´Â ºÏ¹Ì°¡ 2024³â ÁÖ¿ä ¼öÀÍ¿øÀÌ µÇ¾ú½À´Ï´Ù.

CRISPR/Cas À¯ÀüÀÚ ½ÃÀå : ¼¼ºÐÈ­ ºÐ¼®

¼¼°è CRISPR ¹× Cas À¯ÀüÀÚ ½ÃÀåÀº Á¦Ç°, ¿ëµµ, ÃÖÁ¾ »ç¿ëÀÚ, Áö¿ªÀ» ±âÁØÀ¸·Î ¼¼ºÐÈ­µË´Ï´Ù.

½ÃÀåÀº Á¦Ç°¿¡ µû¶ó CRISPR Á¦Ç°°ú CRISPR ¼­ºñ½ºÀÇ µÎ °¡Áö ¹üÁÖ·Î ³ª´µ´Âµ¥, CRISPR Á¦Ç°Àº À¯ÀüÀÚ ÆíÁý, ¿¬±¸ ¹× Ä¡·á °³¹ß ºÐ¾ß¿¡¼­ ³Î¸® ÀÀ¿ëµÇ°í ÀÖÀ¸¸ç, ŸÀÇ ÃßÁ¾À» ºÒÇãÇÏ´Â Á¤È®¼º°ú È¿À²¼ºÀ» Á¦°øÇÔÀ¸·Î½á ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ½À´Ï´Ù. »ç¿ëÀÚ Ä£È­ÀûÀΠŰƮ, ½Ã¾à, °í±Þ Cas ´Ü¹éÁúÀÇ °¡¿ë¼ºÀ¸·Î ÀÎÇØ ÀÇ·á, ³ó¾÷, »ý¸í°øÇÐ »ê¾÷ Àü¹Ý¿¡ °ÉÃÄ ±Þ¼ÓÇÑ º¸±ÞÀÌ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù.

½ÃÀåÀº ÃÖÁ¾ »ç¿ëÀÚ¿¡ µû¶ó Á¦¾à ¹× »ý¸í°øÇÐ ±â¾÷, ÇÐ°è ¹× ¿¬±¸±â°ü, CROÀÇ ¼¼ °¡Áö·Î ºÐ·ùµË´Ï´Ù. Á¦¾à ¹× »ý¸í°øÇÐ ±â¾÷µéÀº ½Å¾à°³¹ß, À¯ÀüÀÚ Áúȯ Ä¡·á, °³ÀÎ ¸ÂÃãÇü ÀÇ·á °³¹ßÀ» À§ÇÑ À¯ÀüÀÚ ÆíÁý ±â¼ú¿¡ ´ë±Ô¸ð ÅõÀÚ¸¦ Çϰí ÀÖÀ¸¸ç, ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ½À´Ï´Ù. À̵éÀÇ ÅºÅºÇÑ ¿¬±¸ ÀÎÇÁ¶ó¿Í ÀÓ»ó½ÃÇè¿¡ ´ëÇÑ ÁýÁßÀº Çõ½ÅÀûÀÎ CRISPR ±â¹Ý ¼Ö·ç¼ÇÀÇ »ó¿ëÈ­¸¦ °¡¼ÓÈ­ÇÏ°í ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù.

CRISPR/Cas À¯ÀüÀÚ ½ÃÀå : Áö¿ªº° ºÐ¼®

CRISPR/Cas À¯ÀüÀÚ ½ÃÀåÀº ±â¼ú ¹ßÀü, ¿¬±¸ ÀÚ±Ý, ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©, ½ÃÀå µµÀÔÀÇ Â÷ÀÌ·Î ÀÎÇØ Áö¿ªº°·Î ¶Ñ·ÇÇÑ Â÷À̸¦ º¸À̰í ÀÖ½À´Ï´Ù. ºÏ¹Ì°¡ ¼¼°è ½ÃÀåÀ» ¼±µµÇϰí ÀÖ´Â °ÍÀº À¯ÀüÀÚ ÆíÁý ±â¼ú¿¡ ´ëÇÑ ¸·´ëÇÑ ÅõÀÚ, źźÇÑ »ý¸í°øÇÐ »ê¾÷, Á¤ºÎÀÇ Áö¿ø Á¤Ã¥¿¡ ±âÀÎÇÕ´Ï´Ù. ƯÈ÷ ¹Ì±¹Àº ÁÖ¿ä Á¦¾àȸ»ç¿Í ¿¬±¸±â°ü °£ÀÇ ±¤¹üÀ§ÇÑ Á¶»ç ÀÌ´Ï¼ÅÆ¼ºê¿Í °øµ¿¿¬±¸°¡ ÀÌ·ç¾îÁö°í ÀÖ¾î ¿ìÀ§¸¦ Á¡Çϰí ÀÖ½À´Ï´Ù. ¹Ì±¹ ±¹¸³º¸°Ç¿ø(NIH)¿¡ µû¸£¸é, ¹Ì±¹ Á¤ºÎ´Â ÃÖ±Ù CRISPR °ü·Ã ¿¬±¸ ÇÁ·ÎÁ§Æ®¿¡ 10¾ï ´Þ·¯ ÀÌ»óÀÇ ÀÚ±ÝÀ» ¹èÁ¤Çß½À´Ï´Ù. À¯·´Àº °­·ÂÇÑ Çмú ¿¬±¸ ÀÎÇÁ¶ó¿Í Ä¡·á ÀÀ¿ë ºÐ¾ß¿¡¼­ CRISPR ±â¼úÀÇ Ã¤ÅÃÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ½ÃÀå Á¡À¯À²ÀÌ µÎµå·¯Áö°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù. µ¶ÀÏ, ¿µ±¹, ÇÁ¶û½º¿Í °°Àº ±¹°¡µéÀº ƯÈ÷ ³ó¾÷ »ý¸í°øÇÐ ¹× Á¤¹ÐÀÇ·á ºÐ¾ß¿¡¼­ CRISPR Çõ½ÅÀÇ ÃÖÀü¼±¿¡ ¼­ ÀÖ½À´Ï´Ù. ±×·¯³ª À¯ÀüÀÚ º¯Çü¿¡ ´ëÇÑ ±ÔÁ¦Àû Á¦¾àÀº ¿©ÀüÈ÷ °úÁ¦·Î ³²¾Æ ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº ÁÖ·Î Áß±¹, ÀϺ», Çѱ¹ µîÀÇ ±¹°¡µéÀÇ »ý¸í°øÇÐ »ê¾÷ È®Àå¿¡ ÈûÀÔ¾î ºü¸¥ ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù. Áß±¹Àº ƯÈ÷ ³ó¾÷ ¹× Áúº´ Ä¡·á ºÐ¾ß¿¡¼­ À¯ÀüÀÚ ÆíÁý ¿¬±¸¿Í ÀÓ»ó Àû¿ë¿¡ Àû±ØÀûÀ¸·Î ÅõÀÚÇϸ鼭 ÁÖ¿ä ±â¾÷·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù. ÀÌ Áö¿ª¿¡¼­´Â ½Ä·® ¾Èº¸¿Í °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ ¼ö¿ä°¡ ´õ¿í °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. ¶óƾ¾Æ¸Þ¸®Ä«¿Í Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ½ÅÈï ½ÃÀå¿¡¼­´Â ³ó¾÷ÀÇ ¹ßÀü°ú ÀÇ·áÀÇ Çö´ëÈ­¸¦ ¹è°æÀ¸·Î CRISPR ±â¼úÀÇ Ã¤ÅÃÀÌ Á¡Â÷ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

CRISPR/Cas À¯ÀüÀÚ ½ÃÀå : °æÀï ±¸µµ

CRISPR/Cas À¯ÀüÀÚ ½ÃÀåÀº °æÀïÀÌ Ä¡¿­Çϸç, ±âÁ¸ ±â¾÷¿Í ½Å»ý ¹ÙÀÌ¿ÀÅ×Å© ±â¾÷ÀÌ È¥ÀçµÇ¾î ´Ù¾çÇÑ ¿ëµµ·Î Çõ½ÅÀ» ÃßÁøÇϰí ÀÖ½À´Ï´Ù. ½ÃÀå ¾÷üµéÀº Á¦¾à, »ý¸í°øÇÐ, ³ó¾÷ ºÐ¾ß ¼ö¿ä Áõ°¡¿¡ ´ëÀÀÇϱâ À§ÇØ À¯ÀüÀÚ ÆíÁý ŰƮ, ½Ã¾à, CRISPR °ü·Ã ¼­ºñ½º µî CRISPR ±â¹Ý ÷´Ü Á¦Ç° °³¹ß¿¡ ÁýÁßÇϰí ÀÖ½À´Ï´Ù. ÀÌµé ±â¾÷Àº CRISPR ±â¼úÀÇ Á¤È®¼º, È¿À²¼º, È®À强À» ³ôÀ̱â À§ÇÑ ¿¬±¸°³¹ß¿¡ ¸¹Àº ÅõÀÚ¸¦ Çϰí ÀÖÀ¸¸ç, ÀÌ´Â »ó¾÷È­ ¼º°ø¿¡ ÇʼöÀûÀÔ´Ï´Ù. °æÀï ȯ°æÀº Á¦Ç° Æ÷Æ®Æú¸®¿À¿Í ½ÃÀå µµ´Þ ¹üÀ§¸¦ È®´ëÇϱâ À§ÇÑ Àü·«Àû ÆÄÆ®³Ê½Ê, Á¦ÈÞ, Àμö¸¦ ÅëÇØ Ư¡Áö¾îÁý´Ï´Ù. ÁÖ¿ä ¾÷üµéÀº ¶ÇÇÑ »õ·Î¿î À¯ÀüÀÚ ÆíÁý µµ±¸ ¹× Ä¡·á¹ý °³¹ßÀ» °¡¼ÓÈ­Çϱâ À§ÇØ ÇÐ°è ¹× ¿¬±¸ ±â°ü°ú Çù·ÂÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¾÷üµéÀº °æÀï ¿ìÀ§¸¦ È®º¸Çϱâ À§ÇØ »ê¾÷ »ý¸í°øÇÐ ¹× ȯ°æ ÀÀ¿ë ºÐ¾ß¿Í °°Àº ÀüÅëÀûÀÎ ÀÇ·á ¹× ³ó¾÷ ÀÌ¿ÜÀÇ ¿ëµµ¸¦ ¸ð»öÇÏ¿© Á¦Ç°À» ´Ù¾çÈ­Çϰí ÀÖÀ¸¸ç, CRISPR ±â¹Ý Ä¡·áÁ¦ ¹× ³ó»ê¹°¿¡ ´ëÇÑ ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎÀÌ ÁøÇàµÊ¿¡ µû¶ó ½ÃÀå °ü°èÀÚµéÀº ½ÅÈï ½ÃÀå¿¡¼­ Àå±âÀûÀÎ ¼ºÀåÀ» ¸ñÇ¥·Î Çϰí ÀÖ½À´Ï´Ù. Àå±âÀûÀÎ ¼ºÀåÀ» ¸ñÇ¥·Î Çϰí ÀÖÀ¸¸ç, ´Ù¾çÇÑ ±ÔÁ¦ ȯ°æÀ» ±Øº¹Çϱâ À§ÇÑ ±âȸ¿Í µµÀüÀÌ ¸ðµÎ Á¸ÀçÇÕ´Ï´Ù. Àü¹ÝÀûÀ¸·Î ±â¼ú ¹ßÀü, Çõ½Å, Àü·«Àû »ç¾÷ È®ÀåÀ» ÅëÇØ °æÀïÀÌ Ä¡¿­ÇØÁö°í ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå CRISPR/Cas À¯ÀüÀÚ ½ÃÀå °³¿ä

  • Á¶»ç ¹üÀ§
  • ½ÃÀå ÃßÁ¤ ±â°£

Á¦2Àå ÁÖ¿ä ¿ä¾à

  • ½ÃÀå ³»¿ª
  • °æÀï ÀλçÀÌÆ®

Á¦3Àå CRISPR/Cas À¯ÀüÀÚ ÁÖ¿ä ½ÃÀå µ¿Çâ

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ½ÃÀå ±âȸ
  • ½ÃÀåÀÇ ÇâÈÄ µ¿Çâ

Á¦4Àå CRISPR/Cas À¯ÀüÀÚ ½ÃÀå : »ê¾÷ ºÐ¼®

  • PEST ºÐ¼®
  • PorterÀÇ Five Forces ºÐ¼®
  • ½ÃÀå ¼ºÀå Àü¸Á : ¸ÊÇÎ
  • ±ÔÁ¦ üÁ¦ ºÐ¼®

Á¦5Àå CRISPR/Cas À¯ÀüÀÚ ½ÃÀå : ³ô¾ÆÁö´Â ÁöÁ¤ÇÐÀû ±äÀåÀÇ ¿µÇâ

  • COVID-19 ÆÒµ¥¹ÍÀÇ ¿µÇâ
  • ·¯½Ã¾Æ-¿ìÅ©¶óÀ̳ª ÀüÀïÀÇ ¿µÇâ
  • Áßµ¿ ºÐÀïÀÇ ¿µÇâ

Á¦6Àå CRISPR/Cas À¯ÀüÀÚ ½ÃÀå ±¸µµ

  • CRISPR/Cas À¯ÀüÀÚ ½ÃÀå Á¡À¯À² ºÐ¼®(2024³â)
  • ÁÖ¿ä Á¦Á¶¾÷üº° ºÐ¼® µ¥ÀÌÅÍ
    • ±âÁ¸ ±â¾÷ ºÐ¼®
    • ½Å±Ô ±â¾÷ ºÐ¼®

Á¦7Àå CRISPR/Cas À¯ÀüÀÚ ½ÃÀå : Á¦Ç°º°

  • °³¿ä
    • ºÎ¹®º° Á¡À¯À² ºÐ¼® : Á¦Ç°º°
    • CRISPR Á¦Ç°
    • CRISPR ¼­ºñ½º

Á¦8Àå CRISPR/Cas À¯ÀüÀÚ ½ÃÀå : ¿ëµµº°

  • °³¿ä
    • ºÎ¹®º° Á¡À¯À² ºÐ¼® : ¿ëµµº°
    • ¹ÙÀÌ¿ÀÀǾàǰ ¿ëµµ
    • ³ó¾÷ ¿ëµµ
    • »ê¾÷ ¿ëµµ

Á¦9Àå CRISPR/Cas À¯ÀüÀÚ ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • °³¿ä
    • ºÎ¹®º° Á¡À¯À² ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚº°
    • Á¦¾à ±â¾÷ ¹× ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷
    • Çмú±â°ü ¹× ¿¬±¸±â°ü
    • CRO(ÀǾàǰ ÀÓ»ó½ÃÇè¼öʱâ°ü)

Á¦10Àå CRISPR/Cas À¯ÀüÀÚ ½ÃÀå : Áö¿ªº°

  • ¼­·Ð
  • ºÏ¹Ì
    • °³¿ä
    • ºÏ¹ÌÀÇ ÁÖ¿ä Á¦Á¶¾÷ü
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • °³¿ä
    • À¯·´ÀÇ ÁÖ¿ä Á¦Á¶¾÷ü
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ³×´ú¶õµå
    • ½º¿þµ§
    • ·¯½Ã¾Æ
    • Æú¶õµå
    • ±âŸ
  • ¾Æ½Ã¾ÆÅÂÆò¾ç(APAC)
    • °³¿ä
    • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÁÖ¿ä Á¦Á¶¾÷ü
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • Çѱ¹
    • È£ÁÖ
    • Àεµ³×½Ã¾Æ
    • ű¹
    • Çʸ®ÇÉ
    • ±âŸ
  • ¶óƾ¾Æ¸Þ¸®Ä«(LATAM)
    • °³¿ä
    • ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ ÁÖ¿ä Á¦Á¶¾÷ü
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ¾Æ¸£ÇîÆ¼³ª
    • ÄÝ·Òºñ¾Æ
    • ±âŸ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«(MEA)
    • °³¿ä
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ÁÖ¿ä Á¦Á¶¾÷ü
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • À̽º¶ó¿¤
    • ÅÍŰ
    • ¾ËÁ¦¸®
    • ÀÌÁýÆ®
    • ±âŸ

Á¦11Àå ÁÖ¿ä º¥´õ ºÐ¼® : CRISPR/Cas À¯ÀüÀÚ ¾÷°è

  • °æÀï ´ë½Ãº¸µå
    • °æÀï º¥Ä¡¸¶Å·
    • °æÀï Æ÷Áö¼Å´×
  • ±â¾÷ °³¿ä
    • Thermo Fisher Scientific
    • Editas Medicine
    • CRISPR Therapeutics
    • Intellia Therapeutics
    • Caribou Biosciences
    • Horizon Discovery
    • Synthego Corporation
    • Agilent Technologies
    • GenScript Biotech
    • Takara Bio
    • Promega Corporation
    • MilliporeSigma
    • Bio-Rad Laboratories
    • New England Biolabs
    • Beam Therapeutics
    • Others

Á¦12Àå AnalystViewÀÇ Àü¹æÀ§Àû ºÐ¼®

LSH 25.03.18

REPORT HIGHLIGHT

CRISPR and Cas Gene Market size was valued at US$ 4,899.43 Million in 2024, expanding at a CAGR of 16.90% from 2025 to 2032.

CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) and Cas (CRISPR-associated) Genes form a groundbreaking gene-editing technology that allows precise alterations in DNA sequences. CRISPR acts as a natural immune defense mechanism in bacteria, while Cas proteins (such as Cas9) serve as molecular scissors guided by RNA to cut specific DNA strands. This system's ability to edit genes with unmatched accuracy has revolutionized genetic research and therapeutic development. The need for CRISPR-Cas technology stems from its potential to address genetic disorders by directly modifying faulty genes. Unlike traditional gene therapies, CRISPR is faster, cost-effective, and more precise, making it a superior choice for treating inherited diseases. It plays a pivotal role in personalized medicine, where tailored genetic interventions offer targeted treatment. Moreover, in agriculture, CRISPR enhances crop yields, pest resistance, and nutritional content, improving global food security. CRISPR's importance lies in its vast applications across healthcare, agriculture, and scientific research. It offers hope for curing genetic diseases like cystic fibrosis and sickle cell anemia, drives innovation in cancer immunotherapy, and aids in developing new antiviral treatments. Additionally, it empowers fundamental biological research by enabling detailed studies of gene functions. CRISPR-Cas technology continues to reshape science, holding transformative potential for human health and sustainability.

CRISPR and Cas Gene Market- Market Dynamics

Rising demand for precise gene-editing tools in healthcare and agriculture

The demand for precise gene-editing tools like CRISPR-Cas systems is surging in healthcare and agriculture due to their transformative potential and cost-effectiveness. In healthcare, CRISPR enables groundbreaking therapies for genetic disorders by directly correcting disease-causing mutations. For instance, it has shown promising results in treating sickle cell anemia and beta-thalassemia. Additionally, the technology is pivotal in cancer immunotherapy, where engineered T cells target specific tumor cells, advancing personalized medicine. The global rise in genetic disorders, affecting millions, is a key driver for adopting CRISPR technology in therapeutic research. According to the World Health Organization (WHO), approximately 10,000 monogenic diseases can potentially be treated through gene-editing advancements. In agriculture, CRISPR is redefining crop engineering, allowing scientists to develop pest-resistant, drought-tolerant, and nutritionally enhanced crops to combat food insecurity. It supports sustainable farming by reducing dependence on chemical pesticides and fertilizers. The U.S. Department of Agriculture (USDA) reported in 2023 that gene-edited crops could boost food production by up to 30% over the next decade, emphasizing the technology's potential to address global agricultural challenges. The rising adoption of CRISPR across these sectors is driven by its precision, efficiency, and affordability compared to older techniques like ZFNs and TALENs, making it a game-changer in both medicine and food production.

CRISPR and Cas Gene Market- Key Insights

  • As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 16.90% over the forecast period (2025-2032)
  • Based on Product segmentation, CRISPR Products was predicted to show maximum market share in the year 2024
  • Based on End-User segmentation, Pharmaceutical and Biotechnology Companies was the leading segment in 2024
  • On the basis of region, North America was the leading revenue generator in 2024

CRISPR and Cas Gene Market- Segmentation Analysis:

The Global CRISPR and Cas Gene Market is segmented on the basis of Product, Application, End-User, and Region.

The market is divided into two categories based on Product: CRISPR Products, and CRISPR Services. CRISPR Products dominate the market due to their widespread application in gene editing, research, and therapeutic development, offering unmatched precision and efficiency. The availability of user-friendly kits, reagents, and advanced Cas proteins has driven rapid adoption across healthcare, agriculture, and biotechnology industries.

The market is divided into three categories based on End-User: Pharmaceutical and Biotechnology Companies, Academic and Research Institutions, and Contract Research Organizations. Pharmaceutical and Biotechnology Companies dominate the market due to their extensive investments in gene-editing technologies for drug discovery, genetic disease therapies, and personalized medicine development. Their robust research infrastructure and focus on clinical trials accelerate the commercialization of innovative CRISPR-based solutions, driving market growth.

CRISPR and Cas Gene Market- Geographical Insights:

The CRISPR and Cas gene market exhibits significant regional variations driven by differences in technological advancements, research funding, regulatory frameworks, and market adoption. North America leads the global market, attributed to substantial investments in gene-editing technologies, a robust biotechnology industry, and supportive government policies. The United States, in particular, dominates due to extensive research initiatives and collaborations between leading pharmaceutical companies and research institutions. According to the National Institutes of Health (NIH), the U.S. government allocated over $1 billion in funding for CRISPR-related research projects in recent years. Europe holds a prominent market share, driven by strong academic research infrastructure and rising adoption of CRISPR technologies in therapeutic applications. Countries like Germany, the United Kingdom, and France are at the forefront of CRISPR innovations, particularly in agricultural biotechnology and precision medicine. However, regulatory constraints around genetic modifications remain a challenge. Asia-Pacific is experiencing rapid growth, primarily fueled by expanding biotechnology industries in countries like China, Japan, and South Korea. China has emerged as a major player, with aggressive investments in gene-editing research and clinical applications, especially in agriculture and disease treatment. The region's rising focus on food security and personalized medicine further accelerates demand. Emerging markets in Latin America and the Middle East & Africa are gradually adopting CRISPR technologies, driven by agricultural advancements and healthcare modernization.

CRISPR and Cas Gene Market- Competitive Landscape:

The CRISPR and Cas gene market is highly competitive, with a mix of established players and emerging biotech firms driving innovation across various applications. Companies in the market are focusing on developing advanced CRISPR-based products, such as gene-editing kits, reagents, and CRISPR-related services, to cater to the increasing demand from the pharmaceutical, biotechnology, and agricultural sectors. These companies invest heavily in research and development to enhance the precision, efficiency, and scalability of CRISPR technology, which is vital for successful commercialization. The competitive landscape is characterized by strategic partnerships, collaborations, and acquisitions aimed at expanding product portfolios and market reach. Key players are also engaging in alliances with academic institutions and research organizations to accelerate the development of new gene-editing tools and therapies. In addition, companies are diversifying their offerings by exploring applications beyond traditional healthcare and agriculture, such as industrial biotechnology and environmental applications, to gain a competitive edge. With growing regulatory approval for CRISPR-based therapies and agriculture products, market players are positioning themselves for long-term growth in emerging markets, which presents both opportunities and challenges in navigating diverse regulatory environments. Overall, the competition is intense, driven by technological advancements, innovation, and strategic business expansion.

Recent Developments:

  • In April 2024, Cellistic successfully acquired the STAR-CRISPR Cas-12 gene-editing technology platform and its full intellectual property portfolio from Artisan Bio, enhancing its capabilities in iPSC-based allogeneic cell therapy. This acquisition strengthens Cellistic's position as a leader in gene editing, offering high precision and efficiency in cell therapy development, and allows for custom edits with greater precision than conventional CRISPR technologies.
  • In July 2024, Ncardia acquired STAR-CRISPR technology to enhance gene editing in induced pluripotent stem cells (iPSCs), offering high efficiency in gene knock-ins and knock-outs with minimal off-target effects. This acquisition strengthens their capabilities in drug discovery and regenerative medicine by providing more accurate disease models and advanced cell therapies.
  • In March 2024, Ricoh entered a licensing agreement with ERS Genomics for access to CRISPR/Cas9 genome editing technology in the USA and Japan. This collaboration, combined with Ricoh's acquisition of Elixirgen Scientific, aims to accelerate drug discovery, personalized medicine, and regenerative medicine by leveraging CRISPR to create reliable disease models, improving drug development timelines and success rates.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CRISPR AND CAS GENE MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Thermo Fisher Scientific
  • Editas Medicine
  • CRISPR Therapeutics
  • Intellia Therapeutics
  • Caribou Biosciences
  • Horizon Discovery
  • Synthego Corporation
  • Agilent Technologies
  • GenScript Biotech
  • Takara Bio
  • Promega Corporation
  • MilliporeSigma
  • Bio-Rad Laboratories
  • New England Biolabs
  • Beam Therapeutics
  • Others

GLOBAL CRISPR AND CAS GENE MARKET, BY PRODUCT- MARKET ANALYSIS, 2019 - 2032

  • CRISPR Products
  • CRISPR Services

GLOBAL CRISPR AND CAS GENE MARKET, BY APPLICATION - MARKET ANALYSIS, 2019 - 2032

  • Biomedical Applications
  • Agricultural Applications
  • Industrial Applications

GLOBAL CRISPR AND CAS GENE MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Pharmaceutical and Biotechnology Companies
  • Academic and Research Institutions
  • Contract Research Organizations

GLOBAL CRISPR AND CAS GENE MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. CRISPR and Cas Gene Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. CRISPR and Cas Gene Market Snippet by Product
    • 2.1.2. CRISPR and Cas Gene Market Snippet by Application
    • 2.1.3. CRISPR and Cas Gene Market Snippet by End-User
    • 2.1.4. CRISPR and Cas Gene Market Snippet by Country
    • 2.1.5. CRISPR and Cas Gene Market Snippet by Region
  • 2.2. Competitive Insights

3. CRISPR and Cas Gene Key Market Trends

  • 3.1. CRISPR and Cas Gene Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. CRISPR and Cas Gene Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. CRISPR and Cas Gene Market Opportunities
  • 3.4. CRISPR and Cas Gene Market Future Trends

4. CRISPR and Cas Gene Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. CRISPR and Cas Gene Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. CRISPR and Cas Gene Market Landscape

  • 6.1. CRISPR and Cas Gene Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. CRISPR and Cas Gene Market - By Product

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Product, 2024 & 2032 (%)
    • 7.1.2. CRISPR Products
    • 7.1.3. CRISPR Services

8. CRISPR and Cas Gene Market - By Application

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Application, 2024 & 2032 (%)
    • 8.1.2. Biomedical Applications
    • 8.1.3. Agricultural Applications
    • 8.1.4. Industrial Applications

9. CRISPR and Cas Gene Market - By End-User

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By End-User, 2024 & 2032 (%)
    • 9.1.2. Pharmaceutical and Biotechnology Companies
    • 9.1.3. Academic and Research Institutions
    • 9.1.4. Contract Research Organizations

10. CRISPR and Cas Gene Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. CRISPR and Cas Gene Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. CRISPR and Cas Gene Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.8. UK
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. UK Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 10.3.8.4. UK Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.8.5. UK Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.9. France
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. France Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 10.3.9.4. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.9.5. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.10. Italy
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. Italy Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 10.3.10.4. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.10.5. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.11. Spain
      • 10.3.11.1. Overview
      • 10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.3. Spain Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Spain Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.11.5. Spain Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.12. The Netherlands
      • 10.3.12.1. Overview
      • 10.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.3. The Netherlands Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 10.3.12.4. The Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.12.5. The Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Overview
      • 10.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.13.5. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.14. Russia
      • 10.3.14.1. Overview
      • 10.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.3. Russia Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.14.5. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.15. Poland
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Poland Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.16. Rest of Europe
      • 10.3.16.1. Overview
      • 10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.16.3. Rest of the Europe Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 10.3.16.4. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.16.5. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. CRISPR and Cas Gene Key Manufacturers in Asia Pacific
    • 10.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. APAC Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
    • 10.4.5. APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.4.6. APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.7. China
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. China Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 10.4.7.4. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.7.5. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.8. India
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. India Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 10.4.8.4. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.8.5. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.12. Indonesia
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Indonesia Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.13. Thailand
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Thailand Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.5. Latin America (LATAM)
    • 10.5.1. Overview
    • 10.5.2. CRISPR and Cas Gene Key Manufacturers in Latin America
    • 10.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. LATAM Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
    • 10.5.5. LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.5.6. LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa (MEA)
    • 10.6.1. Overview
    • 10.6.2. CRISPR and Cas Gene Key Manufacturers in Middle East and Africa
    • 10.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. MEA Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
    • 10.6.5. MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.6.6. MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.8. UAE
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. UAE Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 10.6.8.4. UAE Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.8.5. UAE Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Product, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- CRISPR and Cas Gene Industry

  • 11.1. Competitive Dashboard
    • 11.1.1. Competitive Benchmarking
    • 11.1.2. Competitive Positioning
  • 11.2. Company Profiles
    • 11.2.1. Thermo Fisher Scientific
    • 11.2.2. Editas Medicine
    • 11.2.3. CRISPR Therapeutics
    • 11.2.4. Intellia Therapeutics
    • 11.2.5. Caribou Biosciences
    • 11.2.6. Horizon Discovery
    • 11.2.7. Synthego Corporation
    • 11.2.8. Agilent Technologies
    • 11.2.9. GenScript Biotech
    • 11.2.10. Takara Bio
    • 11.2.11. Promega Corporation
    • 11.2.12. MilliporeSigma
    • 11.2.13. Bio-Rad Laboratories
    • 11.2.14. New England Biolabs
    • 11.2.15. Beam Therapeutics
    • 11.2.16. Others

12. 360 Degree AnalystView

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦